Ascelia Pharma AB
STO:ACE

Watchlist Manager
Ascelia Pharma AB Logo
Ascelia Pharma AB
STO:ACE
Watchlist
Price: 4.895 SEK 2.3% Market Closed
Market Cap: 568m SEK

EV/EBITDA
Enterprise Value to EBITDA

-7.2
Current
-9.2
Median
5.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-7.2
=
Enterprise Value
511.4m SEK
/
EBITDA
-71.4m SEK
EBITDA Growth EV/EBITDA to Growth
SE
Ascelia Pharma AB
STO:ACE
Average EV/EBITDA: 16.1
Negative Multiple: -7.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 469 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.6
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.1 N/A N/A
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.5 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
32.3
2-Years Forward
EV/EBITDA
-18.5
3-Years Forward
EV/EBITDA
11.3